Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Biomateiral CoROCO:6649 +2.11%77 PS Ratio is 8.48 as of Aug. 06, 2026, which is 55% below its 10-year median of 18.95. GuruFocus rates ROCO:6649 with a GF Score™ of 77/100 and a GF Value™ of NT$59.72 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Taiwan Biomateiral Co ranks worse than 80.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Taiwan Biomateiral Co's share price is NT$36.30.
Taiwan Biomateiral Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$4.28. Hence, Taiwan Biomateiral Co's PS Ratio for today is 8.48.
The historical rank and industry rank for Taiwan Biomateiral Co's PS Ratio or its related term are showing as below:
ROCO:6649'
s PS Ratio Range Over the Past 10 Years
Min: 7.69 Med: 18.95 Max: 5652.85
Current: 8.48
During the past 13 years, Taiwan Biomateiral Co's highest PS Ratio was 5652.85. The lowest was 7.69. And the median was 18.95.
ROCO:6649's PS Ratio is ranked worse than 80.85% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.98
vs ROCO:6649: 8.48
During the past 12 months, the average Revenue per Share Growth Rate of Taiwan Biomateiral Co was 22.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 18.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 42.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 65.20% per year.
During the past 13 years, Taiwan Biomateiral Co's highest 3-Year average Revenue per Share Growth Rate was 240.50% per year. The lowest was -21.00% per year. And the median was 65.15% per year.
Taiwan Biomateiral Co (ROCO:6649) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Taiwan Biomateiral Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Taiwan Biomateiral Co's Share Price of today is NT$36.30. Taiwan Biomateiral Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Taiwan Biomateiral Co (ROCO:6649) has a PS Ratio of 8.48 as of Aug. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taiwan Biomateiral Co and its competitors. This is 55% below median its historical median of 18.95. Over the past decade, Taiwan Biomateiral Co's PS Ratio has ranged from 7.69 to 5,652.85. According to the industry distribution chart, Taiwan Biomateiral Co ranks #650 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 80.8%.
Is Taiwan Biomateiral Co's PS Ratio too high?
Taiwan Biomateiral Co's current PS Ratio of 8.48 is 55% below median its 10-year median of 18.95. Over the past 10 years, this metric has ranged from a low of 7.69 to a high of 5,652.85. The Medical Devices & Instruments industry median PS Ratio is 2.98. Taiwan Biomateiral Co's value of 8.48 is 184.6% above this industry median. Based on the distribution chart, Taiwan Biomateiral Co ranks #650 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Taiwan Biomateiral Co has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Biomateiral Co ranks #650 out of 804 companies for PS Ratio. This places Taiwan Biomateiral Co in the lower half of its industry. The industry median PS Ratio is 2.98. Taiwan Biomateiral Co's value of 8.48 is 184.6% above this benchmark. Historically, Taiwan Biomateiral Co's own PS Ratio has ranged from 7.69 to 5,652.85 over the past decade. While the company's 10-year median is 18.95 vs. the industry median of 2.98, Taiwan Biomateiral Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.98, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Biomateiral Co's current PS Ratio of 8.48 is 184.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Taiwan Biomateiral Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Biomateiral Co's current PS Ratio is 8.48, which is 55% below median its own 10-year median of 18.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$59.72, compared to a current price of NT$36.30 — trading 39.2% below its estimated fair value. The current PS Ratio is 8.48, which is 55% below median its 10-year median of 18.95 and 184.6% above the Medical Devices & Instruments industry median of 2.98. Taiwan Biomateiral Co's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current PS Ratio is 8.48 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$36.30 is trading 39.2% below its estimated GF Value™ of NT$59.72.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
PS Ratio: 8.48 (55% below median its 10-year median of 18.95)
GF Value™: NT$59.72 vs. price of NT$36.30 (39.2% below fair value)
Industry Position: 184.6% above the Medical Devices & Instruments median (#650 of 804)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
77GF Score
Get the complete analysis for ROCO:6649
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
